Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis

Authors:
  • SNStanley J. Naides
    Stanley J. Naides
  • VBVivian Bykerk
    Vivian Bykerk
  • KSKatherine A. Siminovitch
    Katherine A. Siminovitch
  • DSDirkjan van Schaardenburg
    Dirkjan van Schaardenburg
  • MBMaarten Boers
    Maarten Boers
  • RLRobert Landewé
    Robert Landewé
  • DHDésirée van der Heijde
    Désirée van der Heijde
  • PTPaul-P. Tak
    Paul-P. Tak
  • MGMark C. Genovese
    Mark C. Genovese
  • MWMichael E. Weinblatt
    Michael E. Weinblatt
  • EKEdward C. Keystone
    Edward C. Keystone

Abstract
Objective.: Serum 14-3-3η is a novel joint-derived proinflammatory mediator implicated in the pathogenesis of rheumatoid arthritis (RA). In our study, we assessed the diagnostic utility of 14-3-3η and its association with standard clinical and serological measures.Methods.: A quantitative ELISA was used to assess 14-3-3η levels. Early (n = 99) and established patients with RA (n = 135) were compared to all controls (n = 385), including healthy subjects (n = 189). The sensitivity, specificity, positive and negative predictive values of 14-3-3η, and the likelihood ratios (LR) for RA were determined through receiver-operator curve analysis. The incremental value of adding 14-3-3η to anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in diagnosing early and established RA was assessed.Results.: Serum 14-3-3η differentiated established patients with RA from healthy individuals and all controls (p < 0.0001). A serum 14-3-3η cutoff of ≥ 0.19 ng/ml delivered a sensitivity and specificity of 77% and 93%, respectively, with corresponding LR positivity of 10.4. At this cutoff in early RA, 64% of patients with early RA were positive for 14-3-3η, with a corresponding specificity of 93% (LR+ of 8.6), while 59% and 57% were positive for ACPA or RF, respectively. When ACPA, RF, and 14-3-3η positivity were used in combination, 77 of the 99 patients (78%) with early RA were positive for any 1 of the 3 markers. Serum 14-3-3η did not correlate with C-reactive protein, erythrocyte sedimentation rate, or Disease Activity Score, but patients who were 14-3-3η-positive had significantly worse disease.Conclusion.: Serum 14-3-3η is a novel RA mechanistic marker that is highly specific, associated with worse disease, and complements current markers, enabling a more accurate diagnosis of RA.

This publication has 16 references indexed in Scilit: